Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
Clinical trial NCT05024266 · UNKNOWN
Trial details
- NCT number
- NCT05024266
- Sponsor
- First Affiliated Hospital of Zhejiang University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-01
- Primary completion
- 2022-08-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.